Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy

Journal of Clinical Oncology

Volumn 23, Issue 32, 2005, Pages 8192-8197

  Lee, Andrew K ^a   D'Amico, Anthony V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER RADIOTHERAPY; DIAGNOSTIC TEST; DISEASE COURSE; GLEASON SCORE; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; KINETICS; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE; MALE; METABOLISM; PROSTATE TUMOR; RISK FACTOR;

HUMANS; MALE; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SALVAGE THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 33644678812     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.0007     Document Type: Review

References (21)

1. Zelefsky MJ, Ben-Porat L. Scher HI, et al: Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 23:826-831, 2005
2. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
3. Pollack A, Zagars GK, Kavadi VS: Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74:670-678, 1994
4. Lee WR, Hanks GE, Hanlon A: Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol 15:230-238, 1997
5. Amling CL, Bergstralh EJ, Blute ML, et al: Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 165:1146-1151, 2001
6. Consensus statement: Guidelines for PSA following radiation therapy: American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
7. Cox JD, Gallagher MJ, Hammond EH, et al: Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy-American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17:1155, 1999
8. Horwitz EM, Vicini FA, Ziaja EL, et al: The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation: American Society of Therapeutic Radiology and Oncology Int J Radiat Oncol Biol Phys 41:267-272, 1998
9. D'Amico AV, Wu Y, Chen MH, et al: Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score
10. Leventis AK, Shariat SF, Kattan MW, et al: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19:1030-1039, 2001
11. Pisansky TM, Kozelsky TF, Myers RP, et al: Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 163:845-850, 2000
12. Stephenson AJ, Shariat SF, Zelefsky MJ, et al: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291:1325-1332, 2004
13. D'Amico AV, Whittington R, Malkowicz SB, et al: Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol 18:3240-3246, 2000
14. Katz MS, Zelefsky MJ, Venkatraman ES, et al: Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21:483-489, 2003
15. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005
16. Zagars GK, Pollack A: Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44:213-221, 1997
17. D'Amico AV, Moul J, Carroll PR, et al: Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172:542-7, 2004
18. Patel A, Dorey F, Franklin J, et al: Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441-1445, 1997
19. Zhou P, Chen MH, McLeod D, et al: Predictors of prostate cancer-specific mortality following radical prostatectomy or radiation therapy. J Clin Oncol 23:3895, 2005 (suppl; abstr 4548)
20. Eggener SE, Roehl KA, Suarez BK, et al: Pre-treatment PSA velocity and risk of cancer progression following radiation therapy for prostate cancer. J Urol 173:311, 2005 (abstr 1144)
21. D'Amico AV, Chen MH, Roehl KA, et al: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135, 2004